The Effect and Mechanism of Fufang Banbianlian Injection in the Treatment of Mesangial Proliferative Glomerulonephritis
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
OBJECTIVE: Mesangial proliferative glomerulonephritis (MsPGN) is an important cause of chronic kidney disease. Abnormal proliferation of mesangial cells and immune-inflammatory response are its important pathological manifestations. Currently, there is no ideal treatment for this disease. Fufang Banbianlian Injection (FBI) has anti-inflammatory, antioxidant, and immuneenhancing effects, and is mostly used for the treatment of bronchitis, pneumonia, and respiratory tract infections in children.
METHODS: A rat model of MsPGN was established and treated with FBI. The efficacy was tested through pathological experiments and urine protein quantification. Network pharmacology methods were used to predict the signaling pathways and key proteins that exert the efficacy of FBI, and were screened through molecular docking experiments. The active substances that work were verified through cell experiments.
RESULTS: The results confirmed that intervention with FBI can inhibit the proliferation of glomerular cells and reduce the infiltration of macrophages, thereby reducing the pathological damage of rats with mesangial proliferative nephritis; it has been found to have an obvious therapeutic effect. Molecular docking results have shown kaempferol (Kae), the main component of FBI, to have a good affinity for key targets. The results of in vitro verification experiments showed that FBI and its active ingredient Kae may play a therapeutic role by regulating the NF-κB signaling pathway in mesangial cells, inhibiting its activation and the secretion of proinflammatory cytokines.
CONCLUSION: Through network pharmacology, molecular docking, and experimental verification, it was confirmed that FBI and its active ingredient Kae can reduce the molecular mechanism of pathological damage of MsPGN by regulating the NF-κB signaling pathway and providing potential therapeutic drugs for the treatment of this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Combinatorial chemistry & high throughput screening - (2024) vom: 08. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chang, Jiakai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fufang banbianlian injection |
|---|
| Anmerkungen: |
Date Revised 11.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113862073272415231119133102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366948334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366948334 | ||
| 003 | DE-627 | ||
| 005 | 20240114234105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113862073272415231119133102 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM366948334 | ||
| 035 | |a (NLM)38204248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chang, Jiakai |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effect and Mechanism of Fufang Banbianlian Injection in the Treatment of Mesangial Proliferative Glomerulonephritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a OBJECTIVE: Mesangial proliferative glomerulonephritis (MsPGN) is an important cause of chronic kidney disease. Abnormal proliferation of mesangial cells and immune-inflammatory response are its important pathological manifestations. Currently, there is no ideal treatment for this disease. Fufang Banbianlian Injection (FBI) has anti-inflammatory, antioxidant, and immuneenhancing effects, and is mostly used for the treatment of bronchitis, pneumonia, and respiratory tract infections in children | ||
| 520 | |a METHODS: A rat model of MsPGN was established and treated with FBI. The efficacy was tested through pathological experiments and urine protein quantification. Network pharmacology methods were used to predict the signaling pathways and key proteins that exert the efficacy of FBI, and were screened through molecular docking experiments. The active substances that work were verified through cell experiments | ||
| 520 | |a RESULTS: The results confirmed that intervention with FBI can inhibit the proliferation of glomerular cells and reduce the infiltration of macrophages, thereby reducing the pathological damage of rats with mesangial proliferative nephritis; it has been found to have an obvious therapeutic effect. Molecular docking results have shown kaempferol (Kae), the main component of FBI, to have a good affinity for key targets. The results of in vitro verification experiments showed that FBI and its active ingredient Kae may play a therapeutic role by regulating the NF-κB signaling pathway in mesangial cells, inhibiting its activation and the secretion of proinflammatory cytokines | ||
| 520 | |a CONCLUSION: Through network pharmacology, molecular docking, and experimental verification, it was confirmed that FBI and its active ingredient Kae can reduce the molecular mechanism of pathological damage of MsPGN by regulating the NF-κB signaling pathway and providing potential therapeutic drugs for the treatment of this disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mesangial proliferative glomerulonephritis | |
| 650 | 4 | |a NF- κB signaling pathway. | |
| 650 | 4 | |a fufang banbianlian injection | |
| 650 | 4 | |a kaempferol | |
| 650 | 4 | |a network pharmacology | |
| 700 | 1 | |a Wu, Lingling |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Lifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jiayi |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Huiming |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jiaona |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Shuwei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiangmei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Combinatorial chemistry & high throughput screening |d 1998 |g (2024) vom: 08. Jan. |w (DE-627)NLM097489352 |x 1875-5402 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113862073272415231119133102 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 01 | ||